|
Targetable genomic mutations in young women with advanced breast cancer. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Roche |
Patents, Royalties, Other Intellectual Property - Submitted patent for HRD calling methodology (Inst) |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Roche |
|
|
Employment - Roche/Foundation Medicine |
Stock and Other Ownership Interests - Roche |
Patents, Royalties, Other Intellectual Property - Patent on IHC; provisional patent on biomarkers and biomarker methodology. |
|
|
Employment - Foundation Medicine |
Leadership - Foundation Medicine |
Stock and Other Ownership Interests - Roche/Genentech |
Travel, Accommodations, Expenses - Foundation Medicine |
|
|
Employment - Foundation Medicine; SeqTech Diagnostics (I) |
Stock and Other Ownership Interests - Roche |
Patents, Royalties, Other Intellectual Property - Royalties from GenomOncology for licensing of MyCancerGenome content |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Roche |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Roche |
|
|
Employment - Foundation Medicine |
Leadership - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
Consulting or Advisory Role - Celsius Therapeutics; Tango Therapeutics |
Research Funding - Foundation Medicine |
|
|
Honoraria - bioTheranostics; Novartis |
Consulting or Advisory Role - Disarm Therapeutics; Pfizer; PledPharma |
Other Relationship - Cynosure/Hologic |
|
|
No Relationships to Disclose |